Loading...

We've got a brand new version of Simply Wall St! Try it out

Sienna Cancer Diagnostics

ASX:SDX
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SDX
ASX
A$13M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Sienna Cancer Diagnostics Limited, a medical technology company, identifies, develops, and commercializes cancer-related in-vitro diagnostic tests for use in pathology laboratories worldwide. The last earnings update was 88 days ago. More info.


Add to Portfolio Compare Print
  • Sienna Cancer Diagnostics has significant price volatility in the past 3 months.
SDX Share Price and Events
7 Day Returns
-15.7%
ASX:SDX
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-49.4%
ASX:SDX
50.9%
AU Biotechs
16.3%
AU Market
SDX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sienna Cancer Diagnostics (SDX) -15.7% -10.4% -12.2% -49.4% - -
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • SDX underperformed the Biotechs industry which returned 50.9% over the past year.
  • SDX underperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
SDX
Industry
5yr Volatility vs Market

SDX Value

 Is Sienna Cancer Diagnostics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sienna Cancer Diagnostics. This is due to cash flow or dividend data being unavailable. The share price is A$0.043.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sienna Cancer Diagnostics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sienna Cancer Diagnostics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:SDX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.01
ASX:SDX Share Price ** ASX (2019-11-18) in AUD A$0.04
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sienna Cancer Diagnostics.

ASX:SDX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:SDX Share Price ÷ EPS (both in AUD)

= 0.04 ÷ -0.01

-4.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sienna Cancer Diagnostics is loss making, we can't compare its value to the Global Biotechs industry average.
  • Sienna Cancer Diagnostics is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Sienna Cancer Diagnostics's expected growth come at a high price?
Raw Data
ASX:SDX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.07x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sienna Cancer Diagnostics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sienna Cancer Diagnostics's assets?
Raw Data
ASX:SDX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.03
ASX:SDX Share Price * ASX (2019-11-18) in AUD A$0.04
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:SDX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:SDX Share Price ÷ Book Value per Share (both in AUD)

= 0.04 ÷ 0.03

1.45x

* Primary Listing of Sienna Cancer Diagnostics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sienna Cancer Diagnostics is good value based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Sienna Cancer Diagnostics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sienna Cancer Diagnostics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SDX Future Performance

 How is Sienna Cancer Diagnostics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sienna Cancer Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sienna Cancer Diagnostics expected to grow at an attractive rate?
  • Unable to compare Sienna Cancer Diagnostics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Sienna Cancer Diagnostics's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Sienna Cancer Diagnostics's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:SDX Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:SDX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:SDX Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 1 -2 -3
2019-03-31 1 -2 -2
2018-12-31 2 -2 -2
2018-09-30 1 -2 -2
2018-06-30 1 -2 -2
2018-03-31 1 -2 -2
2017-12-31 1 -2 -2
2017-09-30 1 -2 -2
2017-06-30 1 -1 -1
2017-03-31 1 0 0
2016-12-31 1 1 0
2016-09-30 1 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Sienna Cancer Diagnostics is high growth as no earnings estimate data is available.
  • Unable to determine if Sienna Cancer Diagnostics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:SDX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Sienna Cancer Diagnostics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:SDX Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.01
2019-03-31 -0.01
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.02
2017-09-30 -0.01
2017-06-30 0.00
2017-03-31 0.00
2016-12-31 0.00
2016-09-30 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sienna Cancer Diagnostics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Sienna Cancer Diagnostics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Sienna Cancer Diagnostics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Sienna Cancer Diagnostics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Sienna Cancer Diagnostics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sienna Cancer Diagnostics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SDX Past Performance

  How has Sienna Cancer Diagnostics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sienna Cancer Diagnostics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sienna Cancer Diagnostics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sienna Cancer Diagnostics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sienna Cancer Diagnostics's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Sienna Cancer Diagnostics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sienna Cancer Diagnostics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:SDX Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 1.04 -2.70 3.51 0.18
2019-03-31 1.38 -2.20 3.25 0.26
2018-12-31 1.71 -1.70 2.99 0.35
2018-09-30 1.46 -1.94 3.01 0.30
2018-06-30 1.22 -2.18 3.04 0.25
2018-03-31 1.00 -2.31 2.95 0.22
2017-12-31 0.78 -2.43 2.87 0.20
2017-09-30 1.11 -1.56 2.51 0.03
2017-06-30 1.44 -0.70 2.16 -0.14
2017-03-31 1.35 -0.40 1.85 -0.17
2016-12-31 1.26 -0.11 1.55 -0.21
2016-09-30 1.29 -0.29 1.57 0.00
2016-06-30 1.33 -0.48 1.59 0.22
2015-06-30 0.93 -1.08 1.86 0.13
2014-06-30 0.80 -0.43 0.84 0.41
2013-06-30 0.43 -0.75 0.92 0.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sienna Cancer Diagnostics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sienna Cancer Diagnostics has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sienna Cancer Diagnostics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sienna Cancer Diagnostics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sienna Cancer Diagnostics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SDX Health

 How is Sienna Cancer Diagnostics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sienna Cancer Diagnostics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sienna Cancer Diagnostics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sienna Cancer Diagnostics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sienna Cancer Diagnostics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Sienna Cancer Diagnostics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sienna Cancer Diagnostics Company Filings, last reported 4 months ago.

ASX:SDX Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 8.58 0.00 4.47
2019-03-31 8.58 0.00 4.47
2018-12-31 8.85 0.00 6.68
2018-09-30 8.85 0.00 6.68
2018-06-30 4.80 0.00 2.69
2018-03-31 4.80 0.00 2.69
2017-12-31 5.56 0.00 3.56
2017-09-30 5.56 0.00 3.56
2017-06-30 2.64 0.00 0.72
2017-03-31 2.64 0.00 0.72
2016-12-31 3.60 0.00 1.65
2016-09-30 3.60 0.00 1.65
2016-06-30 2.18 0.00 1.08
2015-06-30 1.35 0.00 0.79
2014-06-30 0.44 0.00 0.59
2013-06-30 0.87 0.00 0.96
  • Sienna Cancer Diagnostics has no debt.
  • Sienna Cancer Diagnostics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sienna Cancer Diagnostics has sufficient cash runway for 1.4 years based on current free cash flow.
  • Sienna Cancer Diagnostics has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 40.4% each year.
X
Financial health checks
We assess Sienna Cancer Diagnostics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sienna Cancer Diagnostics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SDX Dividends

 What is Sienna Cancer Diagnostics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sienna Cancer Diagnostics dividends.
If you bought A$2,000 of Sienna Cancer Diagnostics shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sienna Cancer Diagnostics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sienna Cancer Diagnostics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:SDX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sienna Cancer Diagnostics has not reported any payouts.
  • Unable to verify if Sienna Cancer Diagnostics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sienna Cancer Diagnostics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sienna Cancer Diagnostics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sienna Cancer Diagnostics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sienna Cancer Diagnostics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sienna Cancer Diagnostics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SDX Management

 What is the CEO of Sienna Cancer Diagnostics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Carl Stubbings
COMPENSATION A$68,637
TENURE AS CEO 0.1 years
CEO Bio

Mr. Carl S. Stubbings, BSc serves as Chief Executive Officer and Managing Director of Sienna Cancer Diagnostics Limited since October 16, 2019. Mr. Stubbings served as Chief Executive Officer at BCAL Diagnostics Pty Ltd. since 2019. Mr. Stubbings served as the Head of Commercialisation at BCAL Diagnostics Pty Ltd. since October 24, 2016 until 2019. He served as Acting Chief Executive Officer of Sienna Cancer Diagnostics Limited from August 2016 to March 2017. He has been Director of Sienna Cancer Diagnostics Limited since December 31, 2011. He serves as an Independent Non-Executive Director at Biomics Biopharma Limited. He serves as a Non-Executive Director of Sienna Diagnostics, providing strategic direction for its high performing cancer diagnostic test. He serves as a Director of Sienna Cancer Diagnostics Unlisted Public Company and Otakaro Pathways New Zealand based Private Company. He serves as a Director of Analytica Medical. He served as Non-Executive Director of Analytica Ltd. from January 13, 2014 to November 30, 2017. He served as the Chief Business Officer of Benitec Biopharma Limited from July 2, 2012 to July 31, 2016, where he focused on developing and executing the commercialisation strategy including licensing and partnership agreements. Mr. Stubbings served as a Vice President of Sales & Marketing at Diasorin Molecular LLC (formerly, Focus Diagnostics, Inc.). Mr. Stubbings joined Focus in 2007. He served as Vice President of Business Development for Panbio Inc. at Inverness Medical Innovations Australia Pty Limited and headed up Panbio Inc. USA. He served as Senior Vice President of Panbio Inc. and served as its Vice President of Business Development since November 6, 2006. He has more than 30 years’ experience in sales and marketing in the health care industry with specific experience in diagnostics, nuclear medicine, life sciences and private pathology. He has specialised in sales with a particular emphasis on marketing across North America, Latin America, Asia Pacific and Europe as well as roles covering manufacturing and administration. He is active member of the Queensland Government’s North American Biotechnology Advisory Council and a member of the American Society of Tropical Medicine and Hygiene. He earned a B.Sc. from Queensland University of Technology, Brisbane, Australia.

CEO Compensation
  • Carl's compensation has increased whilst company is loss making.
  • Carl's remuneration is lower than average for companies of similar size in Australia.
Management Team

Carl Stubbings

TITLE
CEO, MD & Director
COMPENSATION
A$69K
TENURE
0.1 yrs

Tony Di Pietro

TITLE
CFO & Company Secretary
TENURE
5 yrs
Board of Directors Tenure

Average tenure of the Sienna Cancer Diagnostics board of directors in years:

7.9
Average Tenure
  • The tenure for the Sienna Cancer Diagnostics board of directors is about average.
Board of Directors

Geoff Cumming

TITLE
Independent Non-Executive Chairman
COMPENSATION
A$96K
TENURE
13.4 yrs

Carl Stubbings

TITLE
CEO, MD & Director
COMPENSATION
A$69K
TENURE
7.9 yrs

Helen Fisher

TITLE
Independent Non-Executive Director
COMPENSATION
A$64K
TENURE
1.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
29. Oct 19 Buy Merchant Funds Management Pty Ltd Company 05. Mar 19 23. Apr 19 423,522 A$0.07 A$25,698
X
Management checks
We assess Sienna Cancer Diagnostics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sienna Cancer Diagnostics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SDX News

Simply Wall St News

Volatility 101: Should Sienna Cancer Diagnostics (ASX:SDX) Shares Have Dropped 33%?

Investors in Sienna Cancer Diagnostics Limited (ASX:SDX) have tasted that bitter downside in the last year, as the share price dropped 33%. … We've already covered Sienna Cancer Diagnostics's share price action, but we should also mention its total shareholder return (TSR). … We note that Sienna Cancer Diagnostics's TSR, at -30% is higher than its share price return of -33%.

Simply Wall St -

Can We See Significant Insider Ownership On The Sienna Cancer Diagnostics Limited (ASX:SDX) Share Register?

As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.' Sienna Cancer Diagnostics is a smaller company with a market capitalization of AU$17m, so it may still be flying under the radar of many institutional investors. … View our latest analysis for Sienna Cancer Diagnostics ASX:SDX Ownership Summary, May 15th 2019 What Does The Institutional Ownership Tell Us About Sienna Cancer Diagnostics? … Insider Ownership Of Sienna Cancer Diagnostics While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

Did Sienna Cancer Diagnostics Limited (ASX:SDX) Insiders Buy Up More Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Sienna Cancer Diagnostics Limited (ASX:SDX). … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … The Last 12 Months Of Insider Transactions At Sienna Cancer Diagnostics.

Simply Wall St -

Could The Sienna Cancer Diagnostics Limited (ASX:SDX) Ownership Structure Tell Us Something Useful?

Every investor in Sienna Cancer Diagnostics Limited (ASX:SDX) should be aware of the most powerful shareholder groups. … With a market capitalization of AU$17m, Sienna Cancer Diagnostics is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for Sienna Cancer Diagnostics

Simply Wall St -

What does Sienna Cancer Diagnostics Limited's (ASX:SDX) Balance Sheet Tell Us About Its Future?

The direct benefit for Sienna Cancer Diagnostics Limited (ASX:SDX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is SDX growing fast enough to value financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

How Financially Strong Is Sienna Cancer Diagnostics Limited (ASX:SDX)?

The direct benefit for Sienna Cancer Diagnostics Limited (ASX:SDX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Does SDX's growth rate justify its decision for financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

SDX Company Info

Description

Sienna Cancer Diagnostics Limited, a medical technology company, identifies, develops, and commercializes cancer-related in-vitro diagnostic tests for use in pathology laboratories worldwide. The company offers SCD-A7, an anti-human telomerase reverse transcriptase antibody for the detection of the biomarker for cancer. It also provides SIEN-NET technology, a sample preparation platform to enhance the performance of liquid biopsy diagnostic assays. The company has a research collaboration agreement with Minomic International Ltd to develop a proprietary test for the early detection of pancreatic cancer. The company was formerly known as Sienna Capital Ltd and changed its name to Sienna Cancer Diagnostics Limited in 2006. Sienna Cancer Diagnostics Limited was founded in 2002 and is headquartered in Scoresby, Australia.

Details
Name: Sienna Cancer Diagnostics Limited
SDX
Exchange: ASX
Founded: 2002
A$13,007,482
289,055,171
Website: http://www.siennadiagnostics.com.au
Address: Sienna Cancer Diagnostics Limited
Small Technologies Cluster,
1 Dalmore Drive,
Scoresby,
Victoria, 3179,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX SDX Ordinary Shares Australian Securities Exchange AU AUD 03. Aug 2017
CHIA SDX Ordinary Shares Chi-X Australia AU AUD 03. Aug 2017
Number of employees
Current staff
Staff numbers
0
Sienna Cancer Diagnostics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:42
End of day share price update: 2019/11/18 00:00
Last earnings filing: 2019/08/22
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.